

## MDSGene update and expansion:

### Clinical and genetic spectrum of *LRRK2* variants in Parkinson's disease

Clara Krüger, BSc<sup>1</sup>, Shen-Yang Lim, MD<sup>2,3</sup>, Alissa Buhrmann, MSc<sup>1</sup>, Fenja L. Fahrig, BSc<sup>1</sup>, Carolin Gabbert, MSc<sup>1</sup>, Natascha Bahr, BA<sup>1</sup>, Harutyun Madoev, MSc<sup>1</sup>, Connie Marras, MD<sup>4</sup>, Christine Klein, MD<sup>1</sup>, Katja Lohmann, PhD<sup>1,\*</sup>

<sup>1</sup> Institute of Neurogenetics, University of Lübeck, Lübeck, Germany

<sup>2</sup> Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

<sup>3</sup> The Mah Pooi Soo & Tan Chin Nam Centre for Parkinson's & Related Disorders, University of Malaya, Kuala Lumpur, Malaysia.

<sup>4</sup> Edmond J Safra Program in Parkinson's Disease, University Health Network, University of Toronto, Toronto, Canada.

**\*Corresponding author:** Prof. Katja Lohmann, Email: [katja.lohmann@uni-luebeck.de](mailto:katja.lohmann@uni-luebeck.de)

University of Lübeck; Institute of Neurogenetics; Ratzeburger Allee 160; 23538 Lübeck; Germany

## ABSTRACT

Pathogenic variants in the *LRRK2* gene are one of the most commonly identifiable monogenic causes of Parkinson's disease (PD, PARK-LRRK2). This systematic MDSGene literature review comprehensively summarizes published demographic, clinical, and genetic findings related to potentially pathogenic *LRRK2* variants (<https://www.mdsgene.org/>). Recent insights on LRRK2's kinase activity have been incorporated for pathogenicity scoring.

Data on 7,885 individuals with 292 different variants were curated, including 3,296 patients with PD carrying 205 different potentially disease-causing *LRRK2* variants. The initial MDSGene review covered only 724 patients carrying 23 different *LRRK2* variants. Missingness of phenotypic data in the literature was high, hampering the identification of detailed genotype-phenotype correlations. Notably, the median age at onset in the patients with available information was 56 years, with approximately one-third having PD onset <50 years. Tremor was the most frequently reported initial symptom and more frequent than reported in other dominantly inherited forms of PD. Of the 205 potentially disease-causing variants, 14 (6.8%) were classified as pathogenic, 8 (3.9%) as likely pathogenic, and the remaining 183 (89.3%) as variants of uncertain significance (VUS). The pathogenic p.G2019S variant was the most frequent pathogenic variant, followed by p.R1441G and p.R1441C, accounting for >80% of patients, with Tunisia, Spain, and Italy contributing about half of patients.

This systematic review represents the largest database on PARK-LRRK2 to date and provides an important resource to improve precision medicine. Given their high frequency, a better interpretation of the pathogenicity of VUS is needed for selection and stratification of patients in clinical trials.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Introduction

Parkinson's disease (PD) is a relatively common, age-related, neurodegenerative disorder characterized by motor (bradykinesia, resting tremor, rigidity, and postural instability) and non-motor features (neuropsychiatric features, autonomic symptoms, sleep disorders, and sensory dysfunction).<sup>1</sup> The age at onset for almost 25% of affected individuals is younger than 65 years, and for 5–10%, younger than 50 years.<sup>2</sup> Causes of PD include genetic and environmental factors as well as interactions thereof.<sup>2</sup> Monogenic causes, i.e., pathogenic variants in genes such as *LRRK2*, *SNCA*, *VPS35*, *PRKN*, *PINK1*, and *PARK7*, often play a role in patients with early-onset disease.<sup>3,4</sup> Further, risk variants and rare pathogenic variants (often with highly reduced penetrance)<sup>5</sup> in the *GBA1* gene are found in about 10% of PD patients.<sup>6,7</sup> Although monogenic forms comprise a minority of all PD patients<sup>6-8</sup>, they are important as affected individuals are the most likely candidates for potential gene-specific, targeted treatments. These treatments are currently being evaluated in trials<sup>2</sup>, including kinase inhibitors for PD linked to pathogenic variants in the *LRRK2* gene (PARK-LRRK2).<sup>9</sup>

Pathogenic variants in the *LRRK2* gene are one of the most frequent causes of dominantly inherited PD.<sup>10</sup> *LRRK2* (Leucine-Rich Repeat Kinase 2) encodes a multidomain protein kinase that shows autophosphorylation.<sup>11</sup> It plays an important role in different cellular processes, such as cytoskeleton remodeling, vesicular trafficking, autophagy, and protein translation.<sup>12</sup> Increased *LRRK2* kinase activity is thought to dysregulate these processes resulting in the death of dopaminergic neurons in the *substantia nigra*.<sup>13</sup> Until recently, only seven variants in *LRRK2* were considered clearly pathogenic.<sup>4, 14, 15</sup> These variants are mainly located in the guanine triphosphatase (GTPase) Ras-of-complex (ROC) and the kinase domain, which represent two functionally linked enzymatic domains.<sup>10, 16</sup> More recently, in-vivo and in-vitro functional testing of *LRRK2*'s kinase activity became available and revealed approximately 20 additional variants that lead to increased *LRRK2* kinase activity and are thus plausible contributors to the pathogenesis of PD.<sup>16, 17</sup> Importantly, the increased *LRRK2* kinase activity represents a possible therapeutic target.<sup>9, 18</sup> In addition to these pathogenic kinase-activating, gain-of-function variants in *LRRK2*, there are also loss-of-function variants, i.e., nonsense and frameshift variants. However, these truncating variants in *LRRK2* are found with similar frequency in PD patients and controls, indicating that *LRRK2* loss-of-function variants may not alter the risk for PD.<sup>19, 20</sup> Further, copy number variants (CNVs), especially larger deletions, are extremely rarely found in *LRRK2*.<sup>21, 22</sup>

The very large number of scientific publications related to PARK-LRRK2 (>3,000), makes it overwhelming and challenging to follow the literature. Despite the large body of literature, there remain many uncertainties, especially with respect to the phenotypic spectrum and the interpretation of the many genetic variants. These knowledge gaps potentially hamper the identification of PARK-LRRK2 patients who would be eligible for gene-specific clinical trials. Here, we provide a systematic literature review using the protocol of the Movement Disorders Society Genetic Mutation Database (MDSGene) (<https://www.mdsgene.org/>).<sup>23</sup> With this review, we update and considerably extend the MDSGene database to over 200 potentially disease-causing *LRRK2* variants reported in more than 3,000 PD patients. The numbers of included variants and patients have increased approximately tenfold and fourfold, respectively, compared to the initial review covering publications until 2017.<sup>4</sup>

## Materials and Methods

### Literature search and Data Collection Process

For the literature search, we used the PubMed database (<https://pubmed.ncbi.nlm.nih.gov/>). The search term followed the MDSGene's format (Suppl. Table 1), and articles were screened stepwise based on title, abstract, and full text.<sup>24</sup> We included articles that reported at least one individual with a *LRRK2* variant that was considered potentially disease-related by the authors. Further, we evaluated the literature cited in the included articles and used the Human Gene Mutation Database (HGMD) professional (<https://apps.ingenuity.com/ingssso/login>)<sup>25</sup> to identify additional eligible papers.

Demographic, genetic, and clinical information from all eligible papers were extracted using the MDSGene protocol.<sup>4</sup> Evaluated variables are listed in Suppl. Table 2.

### Inclusion and Exclusion Criteria for Patients and Genetic Variants

We only included patients with PD and a potentially pathogenic *LRRK2* variant. Unaffected mutation carriers, patients with atypical parkinsonian disorders (dementia with Lewy bodies [DLB], multiple system atrophy [MSA], progressive supranuclear palsy [PSP], and corticobasal degeneration/syndrome [CBD/CBS]), and patients with non-movement disorder conditions were also extracted but excluded from being displayed on the MDSGene database and from the analyses for PD-related genotype-phenotype correlations. Where authors and patient details suggested duplicate reporting of the same individual, we combined information to create a single entry. Patients who carried additional potentially PD-causing variants were also excluded. Although *LRRK2* is inherited in an autosomal dominant manner, patients with heterozygous and homozygous variants were included as before<sup>4</sup> since previous literature indicated that there is no dosage effect.<sup>26</sup> We excluded *LRRK2* variants that had a minor allele frequency (MAF) of >1% in any ethnicity reported in the gnomAD Browser (<https://gnomad.broadinstitute.org/>). Carriers of benign or likely benign *LRRK2* variants were also excluded.

### Pathogenicity Scoring

All variants were mapped to GRCh37/hg19, and the nomenclature is based on the transcript ENST00000298910 for *LRRK2*. For pathogenicity scoring, we followed the recommendations of the American College of Medical Genetics and Genomics (ACMG).<sup>27</sup> For this, we used two publicly available online tools, i.e., VarSome (<https://varsome.com/>) and Franklin (<https://franklin.genoox.com/>). If there was a discrepancy between the two tools or the score was not plausible, variants were manually scored according to the ACMG recommendations.<sup>27</sup> For this, we applied the CADD score<sup>28</sup> as an in-silico measurement and data from the functional testing for 100 *LRRK2* variants.<sup>16</sup> Variants categorized as “pathogenic”, “likely pathogenic”, or “variant of uncertain significance” (VUS) were considered as potentially disease-causing variants and included in the MDSGene database and the analyses.

## Results

## Included Articles and Study Types

We identified 3,064 publications through the search strategy, carried out for the last time in PubMed on January 10<sup>th</sup>, 2024, and supplemented with articles from HGMD professional v2022.4. An overview of the literature search and the filtering process is shown in Figure 1. At screening, 880 articles were considered eligible for data abstraction. However, 521 did not contain relevant information (Figure 1). The full text of 359 papers was reviewed, but only 291 publications included patients who fulfilled the inclusion criteria (Figure 1).

The most frequently included study types were mutational screens (161/291, 55.3%), followed by case reports or case series (46/291, 15.8%), association studies (35/291, 12.0%), family studies (16/291, 5.5%), and a combination of different designs (33/291, 11.3%).

## Pathogenicity Scoring

A total of 292 *LRRK2* variants were identified on the DNA level corresponding to 291 variants on the protein level since there were two changes (c.5385G>C and c.5385G>T) resulting in the same amino acid substitution (p.L1795F). Of the 292 variants, 290 were scorable using VarSome and Franklin. The remaining two variants and 176 of the 290 variants were manually scored following the ACMG recommendations<sup>27</sup>. There were considerable discrepancies in the pathogenicity scoring between VarSome and Franklin (Figure 2). The manual scoring was closer to Franklin (Figure 2). One reason for the discrepancies was an underestimation in VarSome, which interpreted many VUS erroneously as “likely benign” since the criterion BP1 was applied (“Missense variant in a gene for which primarily truncating variants are known to cause disease”). This is not applicable to *LRRK2*, since loss of function of the protein is not a known disease mechanism.<sup>19, 20</sup> In fact, many missense variants in *LRRK2* have instead been demonstrated to be functionally relevant variants<sup>16</sup>. Using BP1 resulted in scoring almost half of the variants as likely benign by VarSome. Another discrepancy can be explained by an underestimation of likely pathogenic variants, being classified as VUS, in Franklin since the criterion PS3 was not applied (“Well-established in-vitro or in-vivo functional studies supportive of a damaging effect on the gene or gene product.”), even though functional evidence for these variants has become available<sup>16</sup>. In the combined and finally considered classification, the vast majority of the variants were classified as VUS (240/292, 82.2%; Figure 2). A list of all *LRRK2* variants can be found in Suppl. Table 3.

## Included Patients and Variants

A total of 7,885 *LRRK2* variant carriers were identified, and 3,296 PD patients with a potentially pathogenic *LRRK2* variant (41.8%) were included in MDSGene and the analyses, based on the inclusion and exclusion criteria. Among the 7,885 individuals, 75.7% (n=5,969) of them had PD, 1.8% (n=138) had other diseases (see below), and 22.5% (n=1,778) were clinically unaffected. The included 3,296 PD patients carried 205 different variants, of which 14 have been classified as pathogenic (6.8%), 8 as likely pathogenic (3.9%), and 183 as VUS (89.3%; Figure 3).

Of the 205 included variants, missense variants (91.7%, n=188) were the most frequent variant type, followed by intronic variants (2.4%, n=5), nonsense variants (2.0%, n=4), splice region variants (2.0%, n=4), silent changes (1.0%, n=2), splice site variants (0.5%, n=1), and small deletions (0.5%, n=1). Of note, all variants other than missense variants were classified as VUS.

The most frequent variant among the included patients was the p.G2019S substitution, classified as pathogenic, that was present in 2,426 patients (73.6%). Notably, among the clinically unaffected individuals, 739 (41.6%) carried this missense variant, i.e., 739 of 3,165 (23.3%) p.G2019S carriers were unaffected (age at examination unknown for 640 of the unaffected patients, 86.6%). The second most frequently reported variant among the included patients was p.R1441G in 193 patients (5.9%). This variant was also reported in 90 unaffected individuals, which means that 90 of the 283 (31.8%) reported carriers were unaffected (Suppl. Table 4). Since unaffected variant carriers are not systematically reported and have not been extracted from the beginning of the project<sup>4</sup>, no definite conclusion on the penetrance of these variants can be drawn. Nevertheless, incomplete penetrance for p.G2019S and also for p.R1441G plays a considerable role since a large proportion of individuals with these variants had not developed manifest PD at the point of inclusion.

### Excluded Patients and Variants

Notably, among the 7,885 individuals with *LRRK2* variants, 0.3% (n=25) had an atypical parkinsonian disorder, and 1.4% (n=113) had other diseases (such as immunological diseases, cancer, dementia, or essential tremor). These were excluded from the analyses since the sole causative role of the *LRRK2* genotype in these non-PD phenotypes has not been established.

Among the 138 patients with a non-PD phenotype extracted during the systematic literature review, 9 patients also carried a potentially disease-causing variant in another gene. Of the remaining 129 patients, only 20 carried pathogenic or likely pathogenic variants, mostly p.G2019S, 59 carried VUS, and 50 benign or likely benign variants. The phenotypic spectrum of carriers with (likely) pathogenic variants was broad, including MSA (n=3)<sup>29 30</sup>, PSP (n=3)<sup>31-33</sup>, CBD (n=1)<sup>34</sup>, dystonia (n=2)<sup>35 36</sup>, Alzheimer's disease (n=1)<sup>37</sup>, amyotrophic lateral sclerosis (n=2)<sup>38</sup>, restless legs syndrome (n=1)<sup>39</sup>, schizophrenia (n=1)<sup>40</sup>, multiple sclerosis (n=3)<sup>41</sup>, rheumatoid arthritis (n=1)<sup>41</sup>, achalasia (n=1)<sup>41</sup>, and breast cancer (n=1)<sup>42</sup>. Often, these non-PD phenotypes were found in relatives of PD patients with the same *LRRK2* variant. Of note, some of these phenotypes are frequent. Thus, it is also conceivable that there was a co-occur by chance, and these patients show reduced penetrance of the *LRRK2* variant in terms of PD.

Regarding the 25 patients with atypical parkinsonian disorders, 7 patients carried pathogenic *LRRK2* variants (see above), 11 carried VUS, and 7 had benign or likely benign *LRRK2* variants. Among the 18 carriers with potentially disease-causing *LRRK2* variants were 8 MSA, 7 PSP, 2 CBD, and 1 DLB patient(s).

In addition to the rare, presumably monogenically acting variants, three additional coding variants should be mentioned that may increase the risk of developing PD. These include two variants (p.G2385R and p.R1628P) that have repeatedly been shown to act as risk factors for PD in Asian populations.<sup>43,44, 45</sup> The third variant, p.E334K, is frequently observed in the Finnish population and showed increased *LRRK2* kinase activity.<sup>16</sup> These variants have not been included in MDSGene, since their MAF is >1% in certain populations.

We further excluded 44 patients whose genetic cause could not be unequivocally assigned to *LRRK2* since they carried potentially pathogenic variants in at least one other PD gene. This included 18 patients with an additional, potentially disease-causing variant in *GBA1*, and 13 patients with additional *PRKN* variants. Notably, one patient, who, to our knowledge, is the

only case in the literature carrying a large deletion in *LRRK2* (homozygous Exon 49 deletion), also carried a homozygous, pathogenic deletion of Exon 4 in *PRKN*.<sup>22</sup>

## Demographic and Phenotypic Data

One of the biggest challenges for this systematic review was the missing phenotypic data in the majority of publications. Missing data in up to 99.9% of the patients were observed for some of the extracted variables (Figure 4). Even for the four cardinal clinical features of PD, the range of missing data was from 25.3% for bradykinesia to 89.0% for postural instability (Figure 4A).

Among the 3,296 included patients, information on age was available for 762 patients (23.1%) who had a median age of 67 (range 26-95, interquartile range: 58-75) years (the mean age with standard deviation was 65.9±12.2 years). Information on sex was not provided for 1,847 patients (56.0%), among the remaining 1,449 patients, 758 (52.3%) were male. Patients were most commonly European/White (32.8%), Arab (24.1%), or of mixed/other ethnicities (14.9%), based on 1,647 patients with available information (50.0% missing data; Suppl. Figure 1A). Most reported patients originated from Tunisia (26.3%), Spain (14.9%), Italy (6.4%), China (5.9%), or the USA (5.3%) (Suppl. Figure 1B). Notably, among the Tunisian patients, almost all (98.6%, 545/553) carried the p.G2019S variant (median AAO 58 years), while in Spain, about half of the patients carried this variant (47.3%, 148/313, median AAO 62 years) and the other half the p.R1441G variant (49.5%, 155/313, median AAO 56 years). For country-specific distribution of variants, see [https://www.mdsgene.org/d/41/g/4?action=plot\\_map&fc=0&mu=1&country=1](https://www.mdsgene.org/d/41/g/4?action=plot_map&fc=0&mu=1&country=1). A positive family history was reported for almost a third (31.1%) of the PD patients with *LRRK2* variants, it was negative for 21.5% and unknown or not reported for 47.4%.

Information on age at onset (AAO) was available for 1,005 included patients (30.5%). The median age at onset (AAO) was 56 (range 20-95, interquartile range: 47-64) years (Figure 5A, B). While the majority of the patients (67.4%; n=677) had a late onset (≥50 years), approximately one-third (32.5%; n=327) had early-onset PD (EOPD), defined as an AAO after 21 and before 50 years of age.<sup>46</sup> Notably, 9.3% (n=93) of included patients with information even had an AAO <40 years. Although one patient was reported with an AAO of 10 years<sup>47</sup>, it was actually 25 years (personal communication of Dr Lanza). The median disease duration among the included patients was 10 (range 0-42) years. When analyzing only carriers of VUS, the median AAO was 52.5 (range 20-79) years, suggesting that at least a portion of the VUS might also act as a driver of the disease since this AAO is younger than that reported for PD in general.<sup>48</sup> For the group of patients with (likely) pathogenic variants, the median AAO was 56 years (the same as for all included patients, probably due to the high proportion of VUS carriers); the AAO range was 24-95 years. The median AAO of p.G2019S carriers was 57 (range 24-95) years (Figure 5B, Suppl. Table 5).

The data extraction covered 14 motor and seven non-motor symptoms (Suppl. Table 2). Motor symptoms were present in all included patients (per inclusion criterion), while at least one non-motor symptom was present in 9.4%, absent in 0.8%, and information was missing for 89.7% of the included patients. The most frequently reported motor symptom was

bradykinesia, which was indicated as present in 74.4% of the patients and absent in 0.3% (according to the authors, who nevertheless established a diagnosis of PD). This was followed by rigidity (present in 21.0%, absent in 0.3%) and resting tremor (present in 12.4%, absent in 2.3%). Postural instability was the least reported of the four cardinal clinical features and was reported to be present in only 7.8% of the patients (Figure 4A). Among the non-cardinal motor symptoms, dyskinesia (present in 6.5%; absent in 3.1%; median disease duration in patients with dyskinesias: 14 years), motor fluctuations (present in 4.4%; absent in 2.1%; median disease duration in patients with motor fluctuations: 14 years), and dystonia (present in 2.1%; absent in 3.4%) were still relatively frequently reported, but the others were only reported to be present in less than 1% of the included patients with missing data in up to 99.9%, so that no meaningful conclusions can be drawn (Figure 4B). Among the non-motor symptoms, cognitive decline was the most frequently reported, present in 3.6% of the patients (median disease duration 11 years), followed by depression (present in 3.5%, median disease duration 11 years) (Suppl. Table 6). There were no clear differences regarding the frequency of motor and non-motor features in relation to the interpretation of the variant, i.e. (likely) pathogenic (85% of this group were carriers of p.G2019S) vs. VUS (Suppl. Table 7-8, Suppl. Figure 2).

Initial signs and symptoms were reported for 14.9% of the patients only. The most common initial symptom was tremor, which was present in 7.9% of all included patients and in 52.7% of the patients for whom information was available (Figure 5C). This was followed by bradykinesia (in 5.6% of all included patients; in 37.5% of the patients for whom information was available) and rigidity (in 2.4% of all included patients; in 15.9% of the patients for whom information was available). No clear differences were observed between carriers of variants considered (likely) pathogenic and VUS, except that resting tremor in carriers of VUS could be more frequent than in carriers of (likely) pathogenic variants (Suppl. Table 9, Suppl. Figure 3). Further subgroup analyses, for instance, for individual variants, were not meaningful due to the small number of carriers and high degree of missing data.

When comparing features of PARK-LRRK2 to other dominantly inherited forms of PD, i.e., PARK-SNCA or PARK-VPS35, it was noticeable that for all analyzed clinical features, SNCA and VPS35 variant carriers had a higher proportion of symptoms reported as present than LRRK2 variant carriers ([www.mdsgene.org](http://www.mdsgene.org)). In terms of initial presentation, the only difference found between PARK-LRRK2, PARK-SNCA, and PARK-VPS35 was that the most common sign and symptom in both PARK-SNCA (31.2%) and PARK-VPS35 patients (15.9%) was bradykinesia, while in LRRK2 variant carriers, it was tremor (in 52.7% of the patients for whom information was available). Apart from tremor as an initial symptom in PARK-LRRK2, the identification of other clinical clues to the possible presence of PARK-LRRK2 was hampered by the high proportion of missing information in the published literature and needs to be an area of ongoing and future work.

For 26.5% of the patients (n=873, missing information in 73.5%), information was available on whether levodopa treatment was administered (yes for n=850). No information on the treatment response was provided for about half of them (51.5%). For those patients with information (n=412), almost all (95.6%) had a good/excellent response to levodopa (Figure 5D), with no apparent difference between carriers of (likely) pathogenic variants and VUS (Suppl. Table 10, Suppl. Figure 4). Information on other therapies, such as pump therapy or

surgical treatment, including deep brain stimulation (DBS), was rarely available<sup>49</sup> and not systematically analyzed. Reports by other investigators<sup>50, 51</sup>, including pooled analyses<sup>52, 53</sup>, indicate a beneficial effect of DBS in PARK-LRRK2.

## Discussion

This systematic literature review provides a comprehensive and up-to-date review of demographic, clinical, and genetic findings from the published literature on PARK-LRRK2. It is based on curated data from 3,296 patients with 205 different potentially disease-causing variants in *LRRK2*. This represents, by far, the largest database on PARK-LRRK2 to date. A comprehensive overview of *LRRK2* variants and interpretation is of high relevance to clinicians in establishing a possible diagnosis of PARK-LRRK2. This becomes increasingly actionable in light of the identification of several LRRK2 kinase inhibitors (MLi-2 (Merck), DNL-201, DNL-151/BIIB122 (Genentech/Denali), and PF-360 (Pfizer)), including first clinical trials for DNL-201 and DNL-151/BIIB122.<sup>54</sup> The frequent discrepancies between variant interpretation using two automated online tools (i.e., Franklin and Varsome) highlight the value of an expert panel-guided variant interpretation for clinicians and genetic counselors.

Such a comprehensive review can help to identify clinical features to differentiate PARK-LRRK2 from idiopathic PD and other monogenic forms, at least on a group level, since the heterogeneity of the disease, for instance, the AAO ranging widely from 20-95 years, hampers the applicability at the individual level. Notably, the median AAO for PARK-LRRK2 in this review was 56 years, which is lower than the median AAO of 60-75 years reported for PD patients in general<sup>48</sup>, consistent with the notion that monogenic causes for PD typically have earlier AAO.<sup>55</sup> Notably, around one-third of patients had EOPD with onset below age 50 years, thus adding nuance to a prevailing view that *LRRK2* variants cause late-onset PD<sup>56, 57</sup>. Compared to other genes linked to autosomal dominantly inherited PD, PARK-LRRK2 has a later median AAO vs. PARK-SNCA (46 years) but a similar AAO to PARK-VPS35 (52 years) patients ([www.mdsgene.org](http://www.mdsgene.org)). Genetic forms linked to autosomal recessive PD (*PARK7*, *PINK1*, *PRKN*) show even earlier median AAO (27, 31, 32 years; [www.mdsgene.org](http://www.mdsgene.org)).

In this systematic MDSGene review, we included, for the first time, patients with group-level data, i.e., publications in which groups of patients were reported with demographic and clinical data provided in aggregate (as means or percentages for the group but not as individual data). These patients account for 59.2% of the included patients. The disadvantage of the group level data is that they do not contain detailed individual clinical data and thus largely contribute to the high amount of missing data.

Therefore, the major challenge for this systematic literature review was the proportion of missing clinical data. Missingness of demographic and clinical features, such as AAO (information missing in ~70% of patients) and ethnicity (missing in 50%), is an alarming observation. Likewise, the four cardinal motor features were unreported for 25.3% - 89.0% of patients, and information for other motor and non-motor signs and symptoms was even more frequently missing (ranging from 78.6% to 99.9%). This could be linked to the assumption that the authors of the papers with missing data implied the presence of certain symptoms (e.g., the cardinal features) or the absence of symptoms that are only rarely observed, or did not



pay attention to a feature (absence of an examination).<sup>3</sup> Despite these caveats, the reported prevalences of motor response complications and cognitive impairment in PARK-LRRK2 appeared lower in comparison to idiopathic PD. Dyskinesias and motor fluctuations were present in 6.5% and 4.4% of PARK-LRRK2 patients, respectively (with a median disease duration of 14 years), which were quite low compared with the widely quoted estimate of ~10% of levodopa-treated PD patients per year developing motor response complications<sup>45, 58, 59</sup>. Similarly, although cognitive decline was the most frequently reported non-motor symptom in this systematic review, it was reportedly present in only 3.6% of patients (median disease duration 11 years), which was considerably lower than most published studies of idiopathic PD (for example, a recent review estimated that ~20% of PD patients have cognitive impairment at the time of diagnosis, although their overall older age [mean 71.3±7.5 years, vs. 65.9±12.2 years in our study] is likely to have contributed to the higher rate of cognitive impairment.<sup>60</sup> These observations are in line with studies comparing PARK-LRRK2 vs. idiopathic PD that, importantly, have adjusted for multiple potential confounders, including age, disease duration, and levodopa-equivalent dosages.<sup>56, 61, 62</sup>

In this work, a total of 292 *LRRK2* variants were documented in patients with different diseases, and 205 were included and classified as pathogenic, likely pathogenic, or VUS according to the ACMG criteria in patients with PD. Looking at the pathogenicity classifications, another challenge became obvious. As can be seen in Figure 2, the distribution of pathogenicity classifications using a commonly applied tool, i.e., Varsome was quite different from the manually curated one. Varsome often favored the classification of VUS as “likely benign,” which would mean that the patient/variant is not included in MDSGene and not considered for clinical trials. The observed discrepancies underline the need for careful checking of outputs from automated scoring systems by experts in the field<sup>63</sup>. In the manual pathogenicity scoring, all rare variants with a high CADD score were classified as VUS because it cannot be entirely ruled out that they do not affect the development of the disease. However, manual pathogenicity scoring according to ACMG is also challenging, as the criteria for interpretation are subjective and lead to classification inconsistencies.<sup>64</sup> Importantly, the pathogenicity score is only an estimate and based on current knowledge, which may change over time as new insights become available. For example, variants currently classified as VUS may at some point be considered (likely) pathogenic if they are found to segregate in additional families and/or are demonstrated to have relevant functional/biological effects (e.g., elevated *LRRK2* kinase activity). Currently, functional evidence is factored into pathogenicity scoring for a few variants only, since for most variants, little research has been done. One notable example is the novel p.F1700L variant in *LRRK2* with functional support of pathogenicity.<sup>17</sup> Therefore, research studies that examine the impact of different *LRRK2* variants on kinase activity on a large scale<sup>16</sup>, are highly important to the field and are currently being generated.<sup>65</sup>

Correct variant interpretation has great relevance for the application of possible therapies, such as kinase inhibitors for PARK-LRRK2, because only patients who carry a kinase-activating *LRRK2* variant (and perhaps also sporadic PD patients who have biomarker evidence of elevated *LRRK2* kinase activity) will likely respond to kinase inhibitors. Ultimately, understanding the functional impact of specific variants, which, given *LRRK2*'s wide-ranging physiological roles, may extend beyond the effects on kinase activity, is of great importance for the development of novel therapies.<sup>66, 67</sup>

Notably, an increasing number of publications suggest that *LRRK2* has a broader role beyond its link to classical PD. This includes its potential, albeit probably rare<sup>36</sup>, involvement in the pathogenesis of atypical parkinsonian disorders, as underlined by only <20 reported patients with potentially pathogenic variants in *LRRK2*, including MSA<sup>29, 30, 68, 69</sup>, PSP<sup>21, 31-33, 68, 70</sup>, CBD<sup>31, 34</sup>, and DLB<sup>21</sup> patients. Of note, most of these patients carry only VUS (11/18). The possible role of *LRRK2* variants in atypical parkinsonian disorders accords with early observations of a broad pathological spectrum in the brains of patients with *LRRK2* variants, involving aggregation of alpha-synuclein and tau proteins.<sup>71-73</sup> Importantly, long-term follow-up of patients initially diagnosed with PD may reveal additional patients with atypical parkinsonian disorders based on the subsequent clinical course or autopsy results, as illustrated by a patient reported as PD<sup>74</sup>, but later found to have MSA-P<sup>75</sup>. A further link between *LRRK2* and atypical parkinsonian disorders comes from a recently published genome-wide association study (GWAS) involving 1,001 White European-ancestry patients, which suggested a role of common *LRRK2* variation in the survival of PSP patients.<sup>76</sup> Other phenotypes that have been associated with *LRRK2* variants in the literature include essential tremor, where a common variant might act as a risk factor in Asia<sup>77</sup>. Interestingly, *LRRK2* also has a role outside neurological disorders and has repeatedly been linked to inflammatory diseases.<sup>78</sup> Notably, *LRRK2* shows its highest expression in blood and lung, the former also explaining why the functional testing of *LRRK2*'s kinase activity<sup>79</sup> is possible in certain blood cells. A significantly higher incidence of inflammatory diseases like multiple sclerosis and rheumatoid arthritis has been reported<sup>41</sup> and *LRRK2* postulated to be a link between gut inflammation and PD<sup>67, 80</sup>. Several studies have also shown that *LRRK2* is functionally involved in infections with *Mycobacterium tuberculosis*<sup>81, 82</sup> and *Mycobacterium leprae*<sup>83, 84</sup>. The observation of several somatic loss-of-function variants in *LRRK2* in breast cancer cells<sup>42</sup> and germline variants in malignant mesothelioma<sup>85</sup> are also interesting. Notably, patients with non-PD phenotypes often carried VUS or even benign variants, making their disease-causing role, in the sense of a monogenic disease, less clear and warrants further investigation.

Our study had some limitations, including, the unavailability of relevant clinical phenotype information in many cases. For instance, the presence or absence of sleep disorder was reported in only 3.9% of cases, making it challenging to conclude whether rapid eye movement sleep behavior disorder (RBD) - increasingly recognized to be a predictor of poorer prognosis in PD<sup>86</sup> - is less common in PARK-LRRK2 compared to idiopathic PD, as suggested by some authors<sup>56, 87</sup>. Data on impulsive-compulsive behaviors, which are also of clinical relevance, similarly have rarely been reported and, thus, not been collected as part of MDSGene efforts. They need to be described more systematically and will be included in the future. Importantly, they will need to be contextualized with regards to patients' treatment regimes, since dopamine agonist therapy is a primary risk factor for the occurrence of these behaviors. Further, the present MDSGene review can only deal with information at the time of reporting. The lack of confirmation of PD diagnosis by autopsy results and long-term clinical course that are highly relevant<sup>88, 89</sup> is a limitation of this literature-based study. Therefore, dedicated studies are needed to evaluate the role of pathogenic *LRRK2* variants in the development of atypical parkinsonian features. Finally, modifiers of disease penetrance and AAO are areas of major interest but were beyond the scope of this review; for these issues, readers are referred to published works that have examined the effects of other genetic (including polygenic)<sup>90, 91</sup>,

ethno-geographic<sup>92</sup>, and environmental factors<sup>93</sup>, and the interactions thereof<sup>94</sup>. We also did not assess the possible protective effect of LRRK2 p.G2019S among *GBA1* variant carriers<sup>95-97</sup>, which is an intriguing observation that opens up new questions and avenues for research.

In conclusion, we performed a systematic literature review, analyzed the data, and present insights from the largest database on PARK-LRRK2 to date. This review can be used to identify pathogenic variants and elucidate their demographic and phenotypic spectrum. Different filter options are available on the MDSGene website (<https://www.mdsgene.org/>), which also provides published information on in-vivo and in-vitro measurements of LRRK2 kinase activity. This database provides an important resource, especially in light of the emerging molecular-based therapies. However, the missing data, especially detailed clinical information, in the publications and the current limitations in variant interpretation, i.e., the high number of VUS, are important challenges that must be addressed to enable optimal selection and stratification of patients in ongoing and future clinical trials. Thus, this review contributes to improving precision medicine in PARK-LRRK2 patients.

## References

1. LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: Motor and non-motor. *Parkinsonism Relat Disord* 2020;80 Suppl 1:S7-S12.
2. Bloem BR, Okun MS, Klein C. Parkinson's disease. *Lancet* 2021;397:2284-2303.
3. Kasten M, Hartmann C, Hampf J, Schaake S, Westenberger A, Vollstedt EJ, et al. Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. *Mov Disord* 2018;33:730-741.
4. Trinh J, Zeldenrust FMJ, Huang J, Kasten M, Schaake S, Petkovic S, et al. Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. *Mov Disord* 2018;33:1857-1870.
5. Hoglinger G, Schulte C, Jost WH, Storch A, Voitalla D, Kruger R, et al. GBA-associated PD: chances and obstacles for targeted treatment strategies. *J Neural Transm (Vienna)* 2022;129:1219-1233.
6. Westenberger A, Skrahina V, Usnich T, et al. e. Relevance of genetic testing in the gene-targeted trial era: The Rostock Parkinson's Disease Study. *Brain* in press.
7. Cook L, Verbrugge J, Schwantes-An TH, et al. e. Parkinson's Disease Variant Detection and Disclosure: PD GENERation, a North American Study. *Brain* in press.
8. Skrahina V, Gaber H, Vollstedt EJ, Forster TM, Usnich T, Curado F, et al. The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings. *Mov Disord* 2021;36:1005-1010.
9. Jennings D, Huntwork-Rodriguez S, Vissers M, Daryani VM, Diaz D, Goo MS, et al. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. *Mov Disord* 2023;38:386-398.
10. Domingo A, Klein C. Genetics of Parkinson disease. *Handb Clin Neurol* 2018;147:211-227.
11. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc Natl Acad Sci U S A* 2005;102:16842-16847.
12. Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. *Elife* 2016;5.
13. Jeong GR, Lee BD. Pathological Functions of LRRK2 in Parkinson's Disease. *Cells* 2020;9.
14. Aasly JO, Vilarino-Guell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. *Mov Disord* 2010;25:2156-2163.
15. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. *Physiol Rev* 2011;91:1161-1218.
16. Kalogeropoulou AF, Purllyte E, Tonelli F, Lange SM, Wightman M, Prescott AR, et al. Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding. *Biochem J* 2022;479:1759-1783.
17. Borsche M, Pratusciute N, Schaake S, Hinrichs F, Morel G, Uter J, et al. The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity. *Mov Disord* 2023;38:1105-1107.
18. Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. *Science* 2018;360:36-37.
19. Beetz C, Westenberger A, Al-Ali R, Ameziane N, Alhashmi N, Boustany RM, et al. LRRK2 Loss-of-Function Variants in Patients with Rare Diseases: No Evidence for a Phenotypic Impact. *Mov Disord* 2021;36:1029-1031.
20. Blauwendraat C, Reed X, Kia DA, Gan-Or Z, Lesage S, Pihlstrom L, et al. Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. *JAMA Neurol* 2018;75:1416-1422.
21. Landoulsi Z, Pachchek S, Bobbili DR, Pavelka L, May P, Kruger R, et al. Genetic landscape of Parkinson's disease and related diseases in Luxembourg. *Front Aging Neurosci* 2023;15:1282174.
22. Do MD, Tran TN, Luong AB, Le LHG, Van Le T, Le KT, et al. Clinical and genetic analysis of Vietnamese patients diagnosed with early-onset Parkinson's disease. *Brain Behav* 2023;13:e2950.
23. Lill CM, Mashychev A, Hartmann C, Lohmann K, Marras C, Lang AE, et al. Launching the movement disorders society genetic mutation database (MDSGene). *Mov Disord* 2016;31:607-609.
24. Krueger C. Systematic MDSGene literature review: Phenotypic and genetic spectrum of the Parkinson's disease gene LRRK2 (Bachelor's thesis): University of Luebeck, 2023.

25. Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. *Hum Genet* 2017;136:665-677.
26. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. *Mov Disord* 2007;22:55-61.
27. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405-424.
28. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014;46:310-315.
29. Riboldi GM, Palma JA, Cortes E, Iida MA, Sikder T, Henderson B, et al. Early-onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation. *Mov Disord* 2019;34:1080-1082.
30. Carrer T, Bonato G, Sandre M, Emmi A, Campagnolo M, Musso G, et al. Rapidly progressive multiple system atrophy in a patient carrying LRRK2 G2019S mutation. *Neurol Sci* 2024;45:309-313.
31. Sanchez-Contreras M, Heckman MG, Tacik P, Diehl N, Brown PH, Soto-Ortolaza AI, et al. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. *Mov Disord* 2017;32:115-123.
32. Vilas D, Sharp M, Gelpi E, Genis D, Marder KS, Cortes E, et al. Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers. *Mov Disord* 2018;33:335-338.
33. Spanaki C, Latsoudis H, Plaitakis A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. *Neurology* 2006;67:1518-1519.
34. Chen-Plotkin AS, Yuan W, Anderson C, McCarty Wood E, Hurtig HI, Clark CM, et al. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. *Neurology* 2008;70:521-527.
35. Diaz-Feliz L, Feliz-Feliz C, Del Val J, Avila-Fernandez A, Lorda-Sanchez I, Garcia-Ruiz PJ. Generalized dystonia without Parkinsonism in an LRRK2 carrier. *Clin Park Relat Disord* 2022;7:100157.
36. Hernandez D, Pisan Ruiz C, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, et al. The dardarin G2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. *Neurosci Lett* 2005;389:137-139.
37. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, et al. Lrrk2 and Lewy body disease. *Ann Neurol* 2006;59:388-393.
38. Olsen CG, Busk OL, Holla OL, Tveten K, Holmoy T, Tysnes OB, et al. Genetic overlap between ALS and other neurodegenerative or neuromuscular disorders. *Amyotroph Lateral Scler Frontotemporal Degener* 2024;25:177-187.
39. De Rosa A, Guacci A, Peluso S, Del Gaudio L, Massarelli M, Barbato S, et al. A case of restless leg syndrome in a family with LRRK2 gene mutation. *Int J Neurosci* 2013;123:283-285.
40. Takanashi M, Funayama M, Matsuura E, Yoshino H, Li Y, Tsuyama S, et al. Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. *Acta Neuropathol Commun* 2018;6:105.
41. Aasly JO. Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort. *Front Neurosci* 2021;15:634666.
42. Parrilla Castellar ER, Plichta JK, Davis R, Gonzalez-Hunt C, Sanders LH. Somatic Mutations in LRRK2 Identify a Subset of Invasive Mammary Carcinomas Associated with High Mutation Burden. *Am J Pathol* 2020;190:2478-2482.
43. Funayama M, Li Y, Tomiyama H, Yoshino H, Imamichi Y, Yamamoto M, et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. *Neuroreport* 2007;18:273-275.
44. Zhang Y, Sun Q, Yi M, Zhou X, Guo J, Xu Q, et al. Genetic Analysis of LRRK2 R1628P in Parkinson's Disease in Asian Populations. *Parkinsons Dis* 2017;2017:8093124.

45. Lim SY, Tan AH, Ahmad-Annur A, Klein C, Tan LCS, Rosales RL, et al. Parkinson's disease in the Western Pacific Region. *Lancet Neurol* 2019;18:865-879.
46. Mehanna R, Smilowska K, Fleisher J, Post B, Hatano T, Pimentel Piemonte ME, et al. Age Cutoff for Early-Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease. *Mov Disord Clin Pract* 2022;9:869-878.
47. Salemi M, Lanza G, Salluzzo MG, Schillaci FA, Di Blasi FD, Cordella A, et al. A Next-Generation Sequencing Study in a Cohort of Sicilian Patients with Parkinson's Disease. *Biomedicines* 2023;11.
48. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. *J Neural Transm (Vienna)* 2017;124:901-905.
49. Over L, Bruggemann N, Lohmann K. Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review. *J Neuromuscul Dis* 2021;8:341-356.
50. Prendes Fernandez P, Blazquez Estrada M, Sol Alvarez J, Alvarez Martinez V, Suarez San Martin E, Garcia Fernandez C, et al. Analysis of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with monogenic PRKN and LRRK2 forms of Parkinson's disease. *Parkinsonism Relat Disord* 2023;107:105282.
51. Leaver K, Viser A, Kopell BH, Ortega RA, Miravite J, Okun MS, et al. Clinical profiles and outcomes of deep brain stimulation in G2019S LRRK2 Parkinson disease. *J Neurosurg* 2021:1-8.
52. Artusi CA, Dwivedi AK, Romagnolo A, Pal G, Kauffman M, Mata I, et al. Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2019;2:e187800.
53. Chan GH. The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson's Disease: A Mini-Review. *Front Aging Neurosci* 2022;14:895430.
54. Lesniak RK, Nichols RJ, Montine TJ. Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk. *Front Neurol* 2022;13:1016040.
55. Vollstedt EJ, Schaake S, Lohmann K, Padmanabhan S, Brice A, Lesage S, et al. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort. *Mov Disord* 2023;38:286-303.
56. Sosero YL, Gan-Or Z. LRRK2 and Parkinson's disease: from genetics to targeted therapy. *Ann Clin Transl Neurol* 2023;10:850-864.
57. Mata I, Salles P, Cornejo-Olivas M, Saffie P, Ross OA, Reed X, et al. LRRK2: Genetic mechanisms vs genetic subtypes. *Handb Clin Neurol* 2023;193:133-154.
58. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkman J, et al. Parkinson disease. *Nat Rev Dis Primers* 2017;3:17013.
59. Olanow CW, Stocchi F. Levodopa: A new look at an old friend. *Mov Disord* 2018;33:859-866.
60. Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. Parkinson disease-associated cognitive impairment. *Nat Rev Dis Primers* 2021;7:47.
61. Alcalay RN, Mejia-Santana H, Mirelman A, Saunders-Pullman R, Raymond D, Palmese C, et al. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. *Parkinsonism Relat Disord* 2015;21:106-110.
62. Saunders-Pullman R, Mirelman A, Alcalay RN, Wang C, Ortega RA, Raymond D, et al. Progression in the LRRK2-Associated Parkinson Disease Population. *JAMA Neurol* 2018;75:312-319.
63. Rivera-Munoz EA, Milko LV, Harrison SM, Azzariti DR, Kurtz CL, Lee K, et al. ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. *Hum Mutat* 2018;39:1614-1622.
64. Amendola LM, Jarvik GP, Leo MC, McLaughlin HM, Akkari Y, Amaral MD, et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. *Am J Hum Genet* 2016;98:1067-1076.
65. Pratusевичute N, Gomes S, Black K, Morel G, Borsche M, Alcalay RN, et al. Identification of over 45 leucine-rich repeat kinase 2 (LRRK2) activating variants. *Movement Disorder Congress. Copenhagen2023*.

66. Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. *Nat Rev Neurol* 2020;16:97-107.
67. Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. *Nat Rev Neurol* 2022;18:476-495.
68. Trinh J, Guella I, McKenzie M, Gustavsson EK, Szu-Tu C, Petersen MS, et al. Novel LRRK2 mutations in Parkinsonism. *Parkinsonism Relat Disord* 2015;21:1119-1121.
69. Lu CS, Chang HC, Weng YH, Chen RS, Bonifati V, Wu-Chou YH. Analysis of the LRRK2 Gly2385Arg variant in primary dystonia and multiple system atrophy in Taiwan. *Parkinsonism Relat Disord* 2008;14:393-396.
70. Bartonikova T, Mensikova K, Kolarikova K, Vodicka R, Vrtel R, Otruba P, et al. New endemic familial parkinsonism in south Moravia, Czech Republic and its genetical background. *Medicine (Baltimore)* 2018;97:e12313.
71. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachsel JC, Lincoln SJ, et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. *Neurology* 2006;67:1506-1508.
72. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 2004;44:601-607.
73. Blauwendraat C, Pletnikova O, Geiger JT, Murphy NA, Abramzon Y, Rudow G, et al. Genetic analysis of neurodegenerative diseases in a pathology cohort. *Neurobiol Aging* 2019;76:214 e211-214 e219.
74. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. *Ann Neurol* 2005;57:918-921.
75. Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S. Familial parkinsonism: study of original Sagami-hara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. *Parkinsonism Relat Disord* 2009;15:300-306.
76. Jabbari E, Koga S, Valentino RR, Reynolds RH, Ferrari R, Tan MMX, et al. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. *Lancet Neurol* 2021;20:107-116.
77. Chao YX, Ng EY, Tan L, Prakash KM, Au WL, Zhao Y, et al. Lrrk2 R1628P variant is a risk factor for essential tremor. *Sci Rep* 2015;5:9029.
78. Tsafaras G, Baekelandt V. The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. *Neurobiol Dis* 2022;172:105806.
79. Fan Y, Howden AJM, Sarhan AR, Lis P, Ito G, Martinez TN, et al. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. *Biochem J* 2018;475:23-44.
80. Hui KY, Fernandez-Hernandez H, Hu J, Schaffner A, Pankratz N, Hsu NY, et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. *Sci Transl Med* 2018;10.
81. Weindel CG, Bell SL, Vail KJ, West KO, Patrick KL, Watson RO. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis. *Elife* 2020;9.
82. Hartlova A, Herbst S, Peltier J, Rodgers A, Bilkei-Gorzo O, Fearn A, et al. LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages. *EMBO J* 2018;37.
83. Zhang FR, Huang W, Chen SM, Sun LD, Liu H, Li Y, et al. Genomewide association study of leprosy. *N Engl J Med* 2009;361:2609-2618.
84. Dallmann-Sauer M, Xu YZ, da Costa ALF, Tao S, Gomes TA, Prata R, et al. Allele-dependent interaction of LRRK2 and NOD2 in leprosy. *PLoS Pathog* 2023;19:e1011260.
85. Cheung M, Kadariya Y, Sementino E, Hall MJ, Cozzi I, Ascoli V, et al. Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. *Hum Mol Genet* 2021;30:1750-1761.
86. Kim Y, Kim YE, Park EO, Shin CW, Kim HJ, Jeon B. REM sleep behavior disorder portends poor prognosis in Parkinson's disease: A systematic review. *J Clin Neurosci* 2018;47:6-13.
87. Kestenbaum M, Alcalay RN. Clinical Features of LRRK2 Carriers with Parkinson's Disease. *Adv Neurobiol* 2017;14:31-48.


88. Postuma RB, Lang AE. The Clinical Diagnosis of Parkinson's Disease-We Are Getting Better. *Mov Disord* 2023;38:515-517.
89. Virameteekul S, Revesz T, Jaunmuktane Z, Warner TT, De Pablo-Fernandez E. Clinical Diagnostic Accuracy of Parkinson's Disease: Where Do We Stand? *Mov Disord* 2023;38:558-566.
90. Iwaki H, Blauwendraat C, Makarious MB, Bandres-Ciga S, Leonard HL, Gibbs JR, et al. Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. *Mov Disord* 2020;35:774-780.
91. Lai D, Alipanahi B, Fontanillas P, Schwantes-An TH, Aasly J, Alcalay RN, et al. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Ann Neurol* 2021;90:76-88.
92. Hentati F, Trinh J, Thompson C, Nosova E, Farrer MJ, Aasly JO. LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. *Neurology* 2014;83:568-569.
93. Lüth T, König IR, Grünewald A, Kasten M, Klein C, Hentati F, et al. Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors. *Mov Disord* 2020;35:1854-1858.
94. Luth T, Gabbert C, Koch S, König IR, Caliebe A, Laabs BH, et al. Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism. *Mov Disord* 2023;38:1837-1849.
95. Yahalom G, Greenbaum L, Israeli-Korn S, Fay-Karmon T, Livneh V, Ruskey JA, et al. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations. *Parkinsonism Relat Disord* 2019;62:179-184.
96. Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, et al. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease. *Mov Disord* 2020;35:1249-1253.
97. Ortega RA, Wang C, Raymond D, Bryant N, Scherzer CR, Thaler A, et al. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression. *JAMA Netw Open* 2021;4:e215845.



## **Acknowledgments**


This work was supported by the International Parkinson and Movement Disorder Society, the Parkinson's Foundation, and the University of Luebeck. Financial disclosure statement: S.Y.L. has received grants from and served as a consultant for the Michael J. Fox Foundation. C.K. serves as a medical advisor to Centogene and Takeda and previously to Retromer Therapeutics and has received Speakers' honoraria from Desitin and Bial. C.M. has received honoraria from the Parkinson's Foundation.

Figure 1



**Figure 1: Flowchart of the literature search.** The number of included and excluded articles at the different steps is indicated.


**Figure 2**



\* The p.L1795F variant is encoded by two different substitutions on the cDNA level (c.5385G>C and c.5385G>T) and was scored separately for each base change.

**Figure 2: Results of the pathogenicity scoring.** Comparison of the ACMG-based pathogenicity scoring of all *LRRK2* variants from VarSome, Franklin, manual ACMG pathogenicity scoring, and the final pathogenicity scoring. \* The scoring was done on the cDNA level. Therefore, the two variants encoding p.L1795F were counted separately.


**Figure 3**




**Figure 3: Potentially pathogenic variants in *LRRK2*.** Schematic representation of the *LRRK2* gene (A) and protein (B) with the localization of the included variants. The position of the variants is indicated by arrows, and the predicted pathogenicity is provided by color (red, pathogenic; black, likely pathogenic; blue, VUS; grey, risk variant).

**Figure 4**

**A**




**B**




**Figure 4: Signs and symptoms in the included patients at last examination. A) Cardinal clinical signs and symptoms in the included PARK-LRRK2 patients. B) Overview of all reported signs and symptoms in the included patients.**

**Figure 5**


**A**




**B**



**C**



**D**



**Figure 5: Other clinical features in the included patients. A)** The age at onset (AAO) distribution is shown in 10-year bands on the x-axis. The number of patients is displayed on the y-axis. The graph shows the distribution for all included PD patients (blue), for the patients with VUS only (grey), and for patients with (likely) pathogenic variants (red). **B)** Box plots for the AAO in the three groups, depicting medians and interquartile ranges. Outlier points are also displayed and are defined as data points that lie outside 1.5 times the interquartile range (IQR) from the lower or upper quartile boundary. **C)** Initial signs and symptoms in the included patients. **D)** Levodopa response quantifications in the included PD patients. The x-axis shows the six divisions of the levodopa response quantifications and the y-axis the number of patients.